Cash Flow Statement
Growth Metrics

Harvard Bioscience (HBIO) Short-term Investments (2018 - 2024)

Harvard Bioscience (HBIO) reported Short-term Investments of $34000.0 for Q2 2024, up 120.0% on a QoQ basis from -$170000.0 in Q4 2018.

Harvard Bioscience (HBIO) has 2 years of Short-term Investments data on file, last reported at $34000.0 in Q2 2024.

  • Quarterly Short-term Investments changed N/A year-over-year to $34000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $34000.0 (changed N/A YoY) and the FY2018 annual result came in at -$170000.0, changed N/A from the prior year.
  • Short-term Investments grew to $34000.0 in Q2 2024 per HBIO's latest filing, from -$170000.0 in the prior quarter.
  • Across five years, Short-term Investments topped out at $34000.0 in Q2 2024 and bottomed at $34000.0 in Q2 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn
10 Harvard Bioscience 25.38 Mn 18.29 Mn 12.24 Mn

Historic Data

Download Data 🔒
DateValue
Jun 30, 2024 34,000.00
Dec 31, 2018 -170,000.00